Skip to main content
. 2015 Oct 26;6(42):44239–44253. doi: 10.18632/oncotarget.6235

Figure 1. Circulating Tfh cells and cell subsets in patients with HCC and HC.

Figure 1

(A) Gating strategies of circulating Tfh cells and their subsets in HCC and HC. (B) Percentage of CXCR5+CD45RAcells in CD4+ lymphocytes in HCC (n = 21) and HC (n = 11). (C) IL-21 concentration in the co-culture supernatant of purified CXCR5+CD45RACD4+CD3+ and IgD+CD27CD19+CD3 cells. (D) Distribution of Th1-like, Th2-like, and Th17-like subsets in circulating Tfh cells in HCC and HC. (D) Ratio of Th1-/Th2-like Tfh subsets and Th17-/Th2-like Tfh subsets in HCC and HC. Red lines in (B), (D) and (E) show the median values.